BioAge Labs, a Phase 2 biotech developing obesity therapies by targeting metabolic aging, raised $198 million by offering 11.0 million shares at $18, within the range of $17 to $19. The company had originally planned to sell 7.5 million shares before raising the number of shares to be offered to 10.5 million on Wednesday morning. Sofinnova was expected to invest $10.6 million in a concurrent private placement, down from $15.0 million originally planned.
BioAge Labs plans to list on the Nasdaq under the symbol BIOA. Goldman Sachs, Morgan Stanley, Jefferies, and Citi acted as joint bookrunners on the deal.
